Patient-Reported Outcome Management Including Surveillance and Intervention in Nutritional Group

Conditions

malnutrition

Huang JX, Xie SW, Qu HM, Feng ZG, Wang XY, Zhao J, Li QF, Jiang Y, Chen F, Li J, Yao SC, Zhang MH, Shen X, Chen XD, Li N, Zhang X, Tian L, Yang M, Tang M, Song CX, Zou BH, Qin SL, Qin R, Cong MH.

2026-05-01

10.1002/cam4.71896

Feasibility of using Simple Diet Self-Assessment Tool (SDSAT) to explore patterns of dietary intake for patients undergoing chemotherapy

Wenjie Zhu, Min Yang, Baohua Zou, Huimin Qu, Hao Yu et al. (23 authors)

Nutrition Journal2025-10-23

10.1186/s12937-025-01223-4

Nutritional management adherence via an ePRO platform in patients with cancer: a machine learning model study.

Xie SW, Huang JX, Qu HM, Feng ZG, Wang XY, Du ZG, Zhang MH, Wei SQ, Li J, Hong LL, Wang LL, Bai JH, Wang KF, Zhang XB, Shen X, Chen XD, Tian L, Zhang X, Yang M, Li N, Tang M, Song CX, Zou BH, Qin SL, Qin R, Cong MH.

2025-07-02

10.1016/j.eclinm.2025.103330

Interventions

experimental group: whole process management of patients' active reporting outcomes (PROs) based on online platform

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. The malignant tumors were diagnosed by pathology and / or cytology within 8 weeks before the group, and the tumor was divided into three-iv stages; 2. Aged >= 18 years, gender is unlimited; 3. The expected life time is more than 3 months; 4. Bone marrow function: the absolute count of neutrophil (ANC) was >= the lower limit of normal value; Platelet (PLT) >= 100 x 10^9/L Hemoglobin (HB) >= 90g/l; Liver function: total serum bilirubin (STB), direct bilirubin (CB) = 55 ml / min; Coagulation function: prothrombin time (PT) International standardized ratio (INR) < ULN x 1.5; 5. Subjects must understand and sign informed consent; 6. Have reading comprehension ability and can complete questionnaire; 7. Voluntarily participate in the study and sign the informed consent in writing.

Exclusion criteria

Exclusion criteria: 1. Severe cardiovascular diseases, including uncontrollable hypertension (BP >= 160 / 95mmhg), unstable angina pectoris, history of myocardial infarction in the past 6 months, congestive heart failure > NYHA II, severe arrhythmia and pericardial effusion; 2. There was dysphagia or recurrent laryngeal nerve injury; 3. Allergic to the contents of oral nutrient solution; 4. Severe liver and/or kidney disease and abnormal glucose metabolism such as severe diabetes mellitus (glycated hemoglobin >= 7.0%); 5. Female patients who are pregnant or breastfeeding; 6. Severe mental illness with poor compliance; 7. Subjects deemed unsuitable for enrollment by the investigator.

Design outcomes

Primary

Measure	Time frame
Survival period;	—

Secondary

Measure	Time frame
weight;Skeletal muscle mass of extremities;	—

Countries

China

Contacts

Public ContactLu Zexin

806211390@qq.com+86 17610876766

Outcome results

None listed